ArticleJCEM case reports2026
Dulaglutide as a Bridging Therapy Before Insulin for Diabetes Following Pancreatectomy on Congenital Hyperinsulinism.
Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hyperinsulinism and postpancreatectomy diabetes (CHI/PPD) refers to diabetes following pancreatectomy to treat hypoglycemia due to congenital hyperinsulinism. Insulin therapy in CHI/PPD may sometimes be challenging because of glucagon deficiency and the dysfunction of the remaining β-cells. In a 16-year-old male patient with CHI/PPD and severe hypoglycemic brain damage, a dulaglutide trial was planned, because some biochemical indices suggested that he was not completely insulin-dependent. Other than transient appetite loss, no adverse events were observed. The patient's hemoglobin A1c level promptly decreased from 6.7% (SI: 49.7 mmol/mol) [reference range, 4.6-6.2% (SI: 26.8-44.3 mmol/mol)] to 5.7%, with temporary, but not persistent, improvement in endogenous insulin secretion. He has been free from exogenous insulin for more than 4 years under dulaglutide. In conclusion, in selected patients with CHI/PPD and reserved β-cell function, dulaglutide may serve as a bridging therapy before insulin introduction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.